Furthermore, the ability of ANA to attenuate pulmonary hypertension in obese male mice but not lean suggests that inhibition of aromatase may influence obesity-induced elevations in pulmonary arterial pressures and thereby modify the mechanisms underlying pulmonary hypertension development. Here, CYP19A1 is linked to pulmonary hypertension.